https://www.selleckchem.com/products/eft-508.html
rearranged/TP53-mutated NSCLC. gene rearrangement with transcriptional superenhancers leads to overexpression and neuroblastoma. No targeted therapy is available for clinical trials in patients with -rearranged neuroblastoma. Anticancer agents exerting the best synergistic anticancer effects with BET bromodomain inhibitors were identified by screening an FDA-approved oncology drug library. The synergistic effects of the BET bromodomain inhibitor OTX015 and the proteasome inhibitor carfilzomib were examined by immunoblot and flow cytomet
Aimer
Commentaire
Partagez
